Reuters accidentally breaks embargo on NEJM Eliquis study

The New England Journal of Medicine was forced to lift the embargo early on a study of the anticoagulant apixaban today after Reuters broke the embargo by 24 hours.

The original story ran sometime this morning. This ran at the end of the refiled Reuters story, which posted at 9:58 Eastern:

(Reuters inadvertently issued the story headlined “New clot preventer works as well as warfarin with less bleeding.” The story was under embargo for 1000 GMT (6:00 a.m. EDT), July 1)

This is Reuters’ second embargo break in the month of June. As I wrote on June 12 in a post about the earlier one:

As has been the case with another embargo break involving my colleagues, I won’t comment beyond what’s publicly available, given the conflict of interest. (The team I lead at Reuters Health broke one in November, I should point out.) Thanks for understanding.